Cell ReportsMolecular BiologyPeer-reviewed journal article
Perturbations in 3D genome organization can promote acquired drug resistance
Anna G. ManjóniD, Stefano Giustino ManzoiD, Stefan PrekovićiD, Leon Potgeter, Tom van SchaikiD, Ning Qing LiuiD, Koen D. Flach, Daniel Peric‐Hupkes, Stacey E. P. JoosteniD, Hans Teunissen, Anoek FriskesiD, Mila IlićiD, Dorine C. HintzeniD, Vinícius H. Franceschini-SantosiD, Wilbert T. ZwartiD, Elzo de WitiD, Bas van SteenseliD, René H. MedemaiD
Abstract
Acquired drug resistance is a major problem in the treatment of cancer. hTERT-immortalized, untransformed RPE-1 (RPE) cells can acquire resistance to taxol by derepressing the ABCB1 gene, encoding for the multidrug transporter P-gP. Here we have investigated how the ABCB1 gene is derepressed. We show that activation of the ABCB1 gene is associated with reduced DNA methylation, reduced H3K9 trimethylation and increased H3K27 acetylation at the ABCB1 promoter. In addition, we find that the ABCB1 locus has moved away from the nuclear lamina in the taxol-resistant cells. This raises the question which of these alterations were causal to derepression. Directly modifying DNA methylation or H3K27 methylation had neither significant effect on ABCB1 expression, nor did it promote drug resistance. In contrast, the disruption of Lamin B Receptor (LBR), a component of the nuclear lamina involved in genome organization, did promote the acquisition of a taxol-resistant phenotype in a subset of cells. Using CRISPRa-mediated gene activation, we could further substantiate a model in which disruption of lamina association renders the ABCB1 gene permissive to derepression. Based on these data we propose a model in which nuclear lamina dissociation of a repressed gene allows for its activation, implying that deregulation of the 3D genome topology could play an important role in tumor evolution and the acquisition of drug resistance.
- organism: human
- assay: DNA methylation
- assay: ChIP-seq
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 23
- FWCI
- 2.19
- Field percentile
- top 10%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m6A-dependent translational upregulation of ABCB1
Elise G. Holvey-Bates, Jesse A. Coker, … Sarmishtha De·bioRxiv·Mar 13, 2026
- BRG1 targeting overcomes ABCC-based multidrug resistance induced by paclitaxel
Karolina Gronkowska, Sylwia Michlewska, … Agnieszka Robaszkiewicz·Journal of Pharmacology and Experimental TherapeuticsPeer-reviewed·Nov 10, 2025
- Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer
Ozlem Yedier-Bayram, Ahmet Cingöz, … Tugba Bagci Onder·Experimental & Molecular MedicinePeer-reviewed·Jun 29, 2025
- Development of Paclitaxel Resistance in Triple-Negative Breast Cancer Is Associated with Extensive DNA Methylation Changes That Are Partially Reversed by Decitabine
Lenka Trnkova, Monika Buríková, … Božena Smolková·Drug Resistance UpdatesPeer-reviewed·Jan 2, 2026
- Epigenetic and 3D Genome Changes Drive Primary Trastuzumab Resistance in HER2+ Breast Cancer
Ningjun Duan, Yijia Hua, … Yongmei Yin·bioRxiv·Apr 28, 2026
- Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate Cancer
B. Cevatemre, I. Bulut, … C. Acilan Ayhan·bioRxiv·Aug 10, 2023